loperamide

P2, N=50, Completed, MedSIR | Active, not recruiting --> Completed

In this study, we demonstrated that Golden Bifid alleviates loperamide-induced constipation by coordinately modulating host transcriptomic profiles, particularly the MAPK and serotonin signaling pathways, and restoring gut microbiota composition and diversity...Additionally, 16S rDNA sequencing demonstrated that the Golden Bifid partially restored gut microbiota structure, increased microbial diversity, and reversed the dysbiosis induced by LOP, notably reducing the abundance of Patescibacteria and modulating microbial taxa at both the phylum and genus levels to resemble the gut microbiota composition of the control group. These findings suggest that Golden Bifid alleviate STC by enhancing c-kit and 5-HT signaling, modulating the MAPK signaling pathway and pathway and restoring gut microbiota balance, offering promising therapeutic potential for STC treatment.

She was advised to rest her bowel and gradually reintroduce oral intake as tolerated, while receiving symptom relief with antiemetics and loperamide for diarrhea. With symptomatic improvement, she was discharged and subsequently reviewed in the clinic. Based on the most recent imaging and evidence of disease progression, a new treatment regimen of exemestane combined with everolimus was initiated.

This study provides evidence that ICS II exerts significant anti-inflammatory and neuroprotective effects. This is achieved by inhibiting the cGAS-STING pathway and suppressing macrophage M1 polarization, suggesting its potential as a therapeutic agent for STC.

P=N/A, N=308, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Aug 2025

Loperamide reduced GI motility of irinotecan treated mice, however tolerance developed with chronic use, consistent with clinical findings of loperamide refractory diarrhea in patients. Irinotecan treatment produced a significant shift in the β diversity of the fecal microbiome that was mitigated by butyrate. The microbial dysbiosis was associated with increases in the mucin degrading bacteria Akkermansia muciniphilia and the hydrogen sulfide producing Desulfovibrio sp10575755 that was reduced with butyrate treatment.

XSD may inhibit oxidative-stress-induced apoptosis in interstitial cells of Cajal by stimulating the phosphoinositide 3-kinase/protein kinase B/nuclear factor erythroid 2-related factor 2 pathway, thereby effectively treating STC.

P=N/A, N=50, Recruiting, Monash University | Not yet recruiting --> Recruiting

5‑Fluorouracil (5‑FU), a cornerstone chemotherapeutic agent used for colorectal cancer therapy, has long been established as a first‑line treatment. LOP was also shown to enhance the sensitivity of HCT8R cells to 5‑FU by activating cellular autophagy, thereby suppressing resistant cell proliferation and migration, promoting apoptosis and reversing drug resistance. Taken together, these findings provide novel insights into the mechanisms underlying 5‑FU resistance, thereby highlighting potential therapeutic strategies for colorectal cancer.

P1, N=60, Recruiting, University of Pennsylvania | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

While third-generation TKIs like osimertinib, lazertinib, and aumolertinib are effective, resistance often arises...Diarrhea is managed with hydration, loperamide, and dose interruption. Infusion-related reactions (IRRs) are treated symptomatically, with epinephrine in severe cases...Pneumonitis is managed by discontinuing amivantamab and using glucocorticoids.ConclusionsAmivantamab is effective for EGFR mutant NSCLC but can cause adverse effects. Understanding these effects and implementing management strategies can optimize outcomes, maintaining treatment efficacy.

Primary prophylactic administration of G-CSF and loperamide resulted in a clinically relevant reduction of the incidence and severity of sacituzumab govitecan-related neutropenia and diarrhea. Gilead Sciences, S.L.U.